tisagenlecleucel
Sign in to saveAlso known as CTL019, marketed as Kymriah, KYMRIAH
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).
In the Vinony graph
Within Vinony's link graph, tisagenlecleucel is referenced by 295 other articles, and connects out to chimeric antigen receptor, B-cell and United States Food and Drug Administration.
It is catalogued under topics including Antineoplastic drugs, Approved gene therapies and CAR T-cell therapy.
Its subject is documented across 10 Wikipedia language editions.
Key facts
- Drug.pronounce
- tis" a jen" lek loo' se/ˌtɪsədʒen'leklusel/
- Drug.tradename
- Kymriah
- Drug.MedlinePlus
- a617053
- Drug.DailyMedID
- Tisagenlecleucel
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XL04
- Drug.legal_AU_comment
- C4 (class 4 biological)
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.elimination_half life
- 16.8 days
- Drug.CAS_number
- 1823078-37-0
- Drug.DrugBank
- DB13881
- Drug.UNII
- Q6C9WHR03O
- Drug.KEGG
- D11386
via Wikipedia infobox
Medication
- Brand names
- Kymriah
- Drug class
- Antineoplastic cell and gene therapy
- Active ingredients
- tisagenlecleucel
- Dosage form
- Injection
Clinical Trials
32 registered- PHASE1TERMINATEDStudy of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsNovartis Pharmaceuticals · NCT03876028
- PHASE2WITHDRAWNStudy of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)Novartis Pharmaceuticals · NCT04456023
- PHASE2ACTIVE_NOT_RECRUITINGStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsNovartis Pharmaceuticals · NCT03876769
- RECRUITINGEffectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesNovartis Pharmaceuticals · NCT05541341
- PHASE2ACTIVE_NOT_RECRUITINGClinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaPeter MacCallum Cancer Centre, Australia · NCT04234061
- PHASE1COMPLETEDTisagenlecleucel In Primary CNS LymphomaMatthew J. Frigault, M.D. · NCT04134117
Wikidata facts
- Instance of
- medication
- Manufacturer
- Novartis
Show 2 more facts
- World Health Organisation international non-proprietary name
- tisagenlecleucel
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- History
- Manufacture
- Society and culture
- Names
- References
- Further reading
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).
The most common serious side effects are cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and decreases in platelets (components that help the blood to clot), hemoglobin (the protein found in red blood cells that carries oxygen around the body) or white blood cells including neutrophils and lymphocytes.
Excerpted from Wikipedia’s “tisagenlecleucel” article, available under the CC BY-SA 4.0 licence.